KDC-MN-206 – Kodiac biolabs

Plain-language summaryIntrigue 71 / 100

Fluvoxamine (Luvox) is an SSRI with a structural backbone unlike the others in its class, developed by Solvay and approved in the US in 1994. It is a first-line drug for OCD and also useful in social anxiety. The pharmacological wrinkle that makes researchers care about it is high-affinity activation of the sigma-1 receptor, an unusual cellular target involved in stress response, neuroprotection, and possibly viral defense. That sigma-1 hook briefly made fluvoxamine a topic of pandemic-era research after small trials suggested it might reduce hospitalization risk in early COVID-19, although larger follow-up trials have been mixed. It also strongly blocks the liver enzyme CYP1A2, which raises blood levels of caffeine, theophylline, and several other common drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

59/100

Approved SSRI with uniquely potent sigma-1 agonism supporting genuine anti-inflammatory and ER stress research

Fluvoxamine’s story has two chapters. Chapter one: a 40-year-old SSRI approved in Switzerland in 1983, on-label for OCD and social anxiety across 80 countries, pharmacology that any psychopharmacology fellow has seen. Chapter two: it carries the highest sigma-1 receptor affinity of any marketed SSRI, Ki approximately 36 nM, roughly 10-fold more potent at sigma-1 than sertraline, and that biological reality opens a research program that has nothing to do with monoamines.

The sigma-1 axis is what we find genuinely interesting here. The sigma-1 receptor is a ligand-regulated chaperone at the mitochondria-associated ER membrane, and that location matters. Agonism at that site modulates the IP3 receptor, stabilizes the IRE1-BiP complex under ER stress, and blunts NLRP3 inflammasome and NF-kappaB-driven cytokine release. These mechanisms are supported across multiple independent lab groups, not single-consortium work. The ER stress angle in particular is underexplored territory for investigators looking for a compound that is both clinically approved and mechanistically interesting. Hashimoto’s translational work and the broader sigma-1 literature give this axis real grounding.

The TOGETHER trial (Reis et al. 2022) made fluvoxamine briefly famous outside psychiatry. A 32 percent relative risk reduction in the composite hospitalization endpoint for COVID-19 outpatients was a real result from a well-designed platform RCT in Brazil. Whether that effect is sigma-1-driven, SSRI-serotonergic, acid sphingomyelinase inhibition, or some combination hasn’t been settled, and thats the interesting part. A well-powered clinical trial with an unresolved mechanistic attribution question is exactly the kind of hook that keeps a serious investigators attention.

What limits the score is age and the settled-ness of the primary indication. Fluvoxamine is 40 years old. The sigma-1 biology was characterized by Narita et al. in 1996, not recent frontier territory. The SSRI literature for OCD, SAD, and MDD is mature to the point of saturation. The sigma-1 mechanistic hypotheses in humans remain largely untested in controlled mechanistic studies. This isn’t a compound where the biology itself is new; it’s one where a secondary mechanism got interesting later, which is a meaningful distinction from something like MOTS-c or the triple incretins.

For bench work, fluvoxamine is a useful sigma-1 probe precisely because it’s Schedule-exempt, clinically approved, and comes with decades of documented human PK and CYP interaction data. That CYP inhibition profile (potent CYP1A2 and CYP2C19 inhibitor, moderate CYP3A4) is actually an asset for certain experimental designs, and working with a compound where the human safety envelope is this well-characterized has practical value for inflammation-biology programs. We’d push investigators toward it for sigma-1 hypothesis testing specifically, not for primary serotonin work where more selective tools exist.

Novelty: 32
Mechanism promise: 60
In-category differentiation: 65
Evidence quality: 72
Translational signal: 68
Research bench value: 62

Rationale Scores primarily on the sigma-1 secondary pharmacology, which is multi-lab validated and mechanistically interesting at the MAM; novelty is constrained by 40 years of clinical history and a saturated SSRI primary indication, with the TOGETHER trial providing useful clinical signal but leaving the sigma-1 attribution question open.

Selective serotonin reuptake inhibitor with high-affinity sigma-1 receptor agonism

A 2-aminoethyl oxime ether SSRI developed at Kali-Duphar as an antidepressant and anti-obsessional agent, distinguished from other serotonin reuptake inhibitors by potent sigma-1 receptor agonism and downstream anti-inflammatory, cytoprotective, and endoplasmic reticulum chaperone activity.

Abstract

Fluvoxamine, the (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime, is a selective serotonin reuptake inhibitor (SSRI) of the 2-aminoethyl oxime ether structural class, first introduced in Switzerland in 1983 as Floxyfral and approved by the United States Food and Drug Administration in December 1994 for the treatment of obsessive-compulsive disorder (OCD). It is marketed in approximately 80 countries under the trade names Luvox, Fevarin, Faverin, Floxyfral, and Dumyrox for indications including OCD, social anxiety disorder (SAD), and major depressive disorder (MDD), with the extended-release formulation (Luvox CR) approved in the United States in 2008 for both OCD and SAD. Fluvoxamine is pharmacologically distinguished from the other marketed SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) by its potent agonism at the sigma-1 receptor, a ligand-regulated endoplasmic reticulum chaperone protein, with a binding affinity (Ki approximately 36 nM) that is the highest of any clinically used SSRI and approximately 10-fold greater than that of sertraline, the next most potent sigma-1 ligand in the class [1, 2]. The sigma-1 receptor activity, formally characterized by Narita et al. (1996) and subsequently extended by multiple laboratory groups in rodent models and by Hashimoto and colleagues in translational studies, drives a pharmacological profile that extends substantially beyond serotonin reuptake inhibition: activation of the sigma-1 receptor chaperone at the mitochondria-associated endoplasmic reticulum membrane (MAM) modulates the inositol 1,4,5-trisphosphate receptor (IP3R), stabilizes the IRE1-BiP complex under endoplasmic reticulum stress, suppresses NLRP3 inflammasome and NF-kappaB-driven proinflammatory cytokine release, and potentiates nerve growth factor-induced neurite outgrowth in neuronal cell models [3, 4, 5]. These properties have positioned fluvoxamine as a candidate for drug repositioning in inflammatory and infectious disease, most notably in the SARS-CoV-2 pandemic, where the TOGETHER trial (Reis et al. 2022) demonstrated a 32 percent relative risk reduction in the composite endpoint of emergency department retention or hospitalization among high-risk COVID-19 outpatients treated with fluvoxamine 100 mg twice daily for 10 days compared to placebo [6]. Pharmacokinetics in humans are characterized by near-complete gastrointestinal absorption, approximately 53 percent oral bioavailability due to first-pass hepatic metabolism, a plasma elimination half-life of 12 to 15 hours after single doses (extended at steady state owing to nonlinear pharmacokinetics from autoinhibition of CYP1A2 and CYP2C19), and oxidative demethylation through CYP2D6 and CYP1A2 followed by glucuronide conjugation and renal excretion [7, 8]. Fluvoxamine is itself a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP3A4 and CYP2C9, producing clinically significant drug-drug interactions with theophylline, tizanidine, alosetron, clozapine, warfarin, and ramelteon, among others [9]. The compound is well tolerated at registered doses; the principal adverse events are nausea (up to 40 percent), somnolence, insomnia, headache, and asthenia, with serotonin syndrome as a rare but serious risk in combination with other serotonergic agents or monoamine oxidase inhibitors. This monograph reviews the chemistry, synthesis, and structural class of fluvoxamine; the dual SSRI and sigma-1 receptor pharmacology in molecular and translational detail; the comprehensive human pharmacokinetic record; the clinical evidence base across OCD, SAD, MDD, COVID-19, and investigational anti-inflammatory indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five serotonergic or sigma-1-active compounds against fluvoxamine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1465Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-206

Fluvoxamine

Abstract

Read the full monograph